Beidi Biotech at CPHI 2026

SHANGHAI, June 2026 — Beidi Biotech successfully participated in CPHI China 2026, engaging with key pharmaceutical professionals and industry partners at this premier global event.

During the exhibition, our team held productive meetings with clients across key international markets, including Europe, the Americas, Southeast Asia, the Middle East, and Africa. These discussions provided valuable, precise insights into regional market trends and specific regulatory requirements across different continents.

With a strong focus on human pharmaceuticals and animal health, Beidi Biotech engaged in targeted dialogues centered around our highly demanded antibiotic portfolio. We received strong interest and excellent feedback on key products, including Oxytetracycline Dihydrate Injectable, Eprinomectin, Doxycycline Hyclate, Amoxicillin Trihydrate, and Ampicillin Trihydrate. Discussions focused closely on supply stability and meeting strict quality compliance standards for these vital global regions.

This event successfully strengthened our global partnerships and opened new avenues for collaboration. Moving forward, we will actively follow up on all inquiries, continuing to support global healthcare through high-quality supply and professional service.